Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Lung Cancer
•
Radiation Oncology
•
Gastrointestinal Cancers
•
Medical Oncology
How would you treat a patient with a synchronous T1N2 non-small cell lung cancer and a T3N1 mid-rectal adenocarcinoma (MMR intact)?
What would be an optimal sequence of therapies, and what chemotherapy regimen may be best?
Related Questions
What are your top takeaways from ASCO GI 2025?
Given that ESOPEC did not mandate PET staging, are the conclusions of the study still applicable for patients who are staged with PET?
In a patient with esophageal cancer with lymph node involvement, would you consider treating with definitive chemo-radiation if they have a single area of retroperitoneal metastasis?
Which GI cancer patients do you use oral contrast in staging CT scans?
In ES-SCLC presenting with extensive brain metastases, how do you time whole brain radiation after the first cycle of chemotherapy has already been delivered?
How are you incorporating Tumor Treating Fields for locally progressive/metastatic NSCLC, if at all?
In a patient with prior RT to the prostate and SVs and newly diagnosed, locally advanced rectal cancer at 10-15 cm, would you offer preoperative chemoradiation?
Would you consider proton therapy as part of TNT for rectal cancer?
Would you offer any adjuvant therapy for a young patient with anal cancer s/p definitive chemoradiation and R0 resection with significant residual disease?
Which patients, if any, treated according to PROSPECT for an early stage rectal cancer, would you offer surveillance if they achieved cCR after neoadjuvant chemotherapy?